2,407 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,407 shares of the biopharmaceutical company’s stock, valued at approximately $318,000.

Other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in Intra-Cellular Therapies by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 359,045 shares of the biopharmaceutical company’s stock worth $29,987,000 after purchasing an additional 8,330 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Intra-Cellular Therapies by 71.6% during the fourth quarter. Jones Financial Companies Lllp now owns 6,590 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 2,750 shares during the last quarter. M&T Bank Corp increased its holdings in shares of Intra-Cellular Therapies by 2.2% during the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 138 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at $1,590,000. Finally, Arizona State Retirement System boosted its holdings in shares of Intra-Cellular Therapies by 0.8% during the 4th quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock valued at $2,302,000 after acquiring an additional 206 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen assumed coverage on Intra-Cellular Therapies in a research report on Thursday, May 15th. They issued a “hold” rating for the company. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $109.70.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.87 on Friday. Intra-Cellular Therapies, Inc. has a 52 week low of $68.98 and a 52 week high of $131.98. The firm’s fifty day moving average is $131.87 and its 200-day moving average is $125.14. The firm has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.